title: Inhibition of terminal N- and O-glycosylation specific for herpesvirus-infected cells: mechanism of an inhibitor of sugar nucleotide transport across Golgi membranes.
abstract: The nucleoside analog (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) inhibited the Golgi-associated terminal glycosylation in herpes simplex virus type 1- and type 2-infected cells, specifically incorporation of galactose and sialic acid into N-linked oligosaccharides, and incorporation of sialic acid and, to a lesser extent, of galactose into O-linked oligo saccharides. This resulted in formation of viral glycoproteins with terminal GlcNAc and Fuc in N-linked oligosaccharides and terminal O-linked GalNAc. Inhibition of formation of UDP-hexoses and of acceptor glycoprotein synthesis and inhibition of cellular transport of viral glycoproteins were not observed. No evidence for the formation of a sugar nucleotide analog of BVdU was obtained. Inhibition required phosphorylation of BVdU to its 5' monophosphate (BVdUMP) by the virus-coded thymidine kinase. In a cell-free system, this monophosphate inhibited the transport of pyrimidine sugar nucleotides across Golgi membranes and, as a consequence, the incorporation of sugars into glycoproteins. Inhibition of galactosyltransferase by BVdUMP was insignificant. BVdUMP did not inhibit translocation across the Golgi membrane of purine sugar nucleotides. Inhibition of sugar nucleotide translocation represents the first target for design of virus-specific glycosylation inhibitors.
authors.affiliation: Department of Clinical Virology, University of Göteborg, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Olofsson
authors.forename: M
authors.initials: M
authors.lastname: Milla
authors.forename: C
authors.initials: C
authors.lastname: Hirschberg
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
authors.forename: R
authors.initials: R
authors.lastname: Datema
mesh_terms: D001692:Biological Transport / Q000187:drug effects; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002460:Cell Line; D005700:Galactosyltransferases / Q000037:antagonists & inhibitors; D006031:Glycosylation; D006056:Golgi Apparatus / Q000502:physiology*; D037102:Lectins; D009702:Nucleoside Diphosphate Sugars / Q000378:metabolism*; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D018139:Simplexvirus / Q000502:physiology*; D014759:Viral Envelope Proteins / Q000096:biosynthesis*
chemical_list: D037102:Lectins; D009702:Nucleoside Diphosphate Sugars; D014759:Viral Envelope Proteins; C045464:glycoprotein G, herpes simplex virus type 2; C038535:glycoprotein gC, herpes simplex virus type 1; C020235:brivudine; D005700:Galactosyltransferases; D001973:Bromodeoxyuridine